FGFR2 mutations are implicated in a variety of cancers. These mutations often lead to aberrant activation of the FGFR2 protein, which can drive uncontrolled cell proliferation and survival. This is particularly notable in cancers such as breast cancer, gastric cancer, and endometrial cancer. The mutations can lead to constant activation of downstream signaling pathways, such as the MAPK and PI3K/AKT pathways, which are crucial for cell growth and survival.
